Table 1 Characteristics of patients with bmCRPC on AA with or without ALP-Bouncing
Variable | all | no ALP-Bouncing | ALP-Bouncing | p |
|---|---|---|---|---|
Patients [n], (%) | 84 | 50 (60) | 34 (40) | - |
Age, median [years] (IQR) | 69.0 (62.3–76.0) | 68.0 (61.0–75.5) | 70.5 (66.5–76.0) | 0.304 |
Lnn. Metastases [n] (%) | 45 (53.6) | 27 (54.0) | 18 (52.9) | 0.924 |
Visceral Metastases [n] (%) | 17 (20.2) | 14 (28.0) | 3 (8.8) | 0.032 |
Pre CTX [n] (%) | 39 (46.4) | 24 (48.0) | 15 (44.1) | 0.726 |
Post CTX [n] (%) | 45 (53.6) | 26 (52.0) | 19 (55.9) | 0.726 |
Patients died [n] (%) | 53 (63.1) | 39 (78.0) | 14 (41.2) | - |
Antiresorptive therapy [n] (%) | 56 (66.7) | 32 (64.0) | 24 (70.6) | 0.530 |
Zoledronic acid [n] (%) | 42 (50.0) | 24 (48.0) | 18 (52.9) | 0.821 |
Denosumab [n] (%) | 14 (16.7) | 8 (16.0) | 6 (17.6) | |
Best clinical outcome [n] (%) | ||||
CR | 1 (1.2) | 0 (0) | 1 (2.9) | <0.001 |
PR | 51 (60.7) | 22 (44.0) | 29 (85.3) | |
SD | 20 (23.8) | 16 (32.0) | 4 (11.8) | |
PD | 12 (14.3) | 12 (24.0) | 0 (0) | |
ECOG (all) [n] (%) | ||||
0 | 12 (14.3) | 7 (14.0) | 5 (14.7) | 0.351 |
1 | 53 (63.1) | 29 (58.0) | 24 (70.6) | |
2 | 29 (22.6) | 14 (28.0) | 5 (14.7) | |
GS ≥ 8 [n] (%)a | 45 (60.8) | 29 (67.4) | 16 (51.6) | 0.169 |
PSA red. ≥ 50 % [n] (%) | 47 (56.0) | 19 (38.0) | 28 (82.4) | <0.001 |
PSA red. ≥ 90 % [n] (%) | 22 (26.2) | 6 (12.0) | 16 (47.1) | <0.001 |
Median PSA Baseline [ng/ml] (IQR) | 174 (55–500) | 105 (47–457) | 151 (54–477) | 0.824 |
Median LDH Baseline [U/l] (IQR) | 287 (223–422) | 290 (228–565) | 252 (218–327) | 0.125 |
Median ALP Baseline [U/l] (IQR) | 155 (102–355) | 171 (96–381) | 154 (114–273) | 0.895 |
ALP rising at 12 w AA [n] (%) | 27 (33.3) | 27 (57.4) | 0 (0) | - |
LDH BL > UNL [n] (%) | 58 (71.6) | 37 (77.1) | 21 (63.6) | 0.187 |
LDH normalization [n] (%) | 23 (39.0) | 10 (27.0) | 13 (59.1) | 0.015 |